|
ES2383954T3
(es)
*
|
2000-01-25 |
2012-06-27 |
Neurocrine Biosciences, Inc |
Antagonistas del receptor de la hormona liberadora de ganodotropina y métodos relacionados con ellos
|
|
ATE557007T1
(de)
*
|
2003-07-07 |
2012-05-15 |
Neurocrine Biosciences Inc |
Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
|
|
EP1646389B1
(en)
*
|
2003-07-07 |
2008-09-10 |
Neurocrine Biosciences, Inc. |
Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
|
|
CA2531507C
(en)
*
|
2003-07-07 |
2013-10-01 |
Neurocrine Biosciences, Inc. |
Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
|
|
CN102127057A
(zh)
*
|
2004-03-15 |
2011-07-20 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
|
EA017029B1
(ru)
|
2007-04-06 |
2012-09-28 |
Ньюрокрайн Байосайенсиз, Инк. |
Антагонисты рецептора гонадотропин-рилизинг-фактора и способы их применения
|
|
AR065947A1
(es)
|
2007-04-06 |
2009-07-15 |
Neurocrine Biosciences Inc |
Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh)
|
|
AU2008307643B9
(en)
|
2007-09-28 |
2014-04-17 |
Intrexon Corporation |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
|
WO2009062087A1
(en)
|
2007-11-07 |
2009-05-14 |
Neurocrine Biosciences, Inc. |
Processes for the preparation of uracil derivatives
|
|
ES2549502T3
(es)
|
2009-11-20 |
2015-10-28 |
Sk Chemicals Co., Ltd. |
Antagonistas de receptores de gonadoliberina, método de fabricación de los mismos, y composición farmacéutica que los contienen
|
|
JP6159870B2
(ja)
|
2013-03-15 |
2017-07-05 |
アッヴィ・インコーポレイテッド |
月経出血過多および子宮類線維腫の処置に使用するための組成物
|
|
EP2881391A1
(en)
|
2013-12-05 |
2015-06-10 |
Bayer Pharma Aktiengesellschaft |
Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
|
|
AU2015308987B2
(en)
|
2014-08-26 |
2021-02-18 |
Betanien Hospital |
Methods, agents and compositions for treatment of inflammatory conditions
|
|
US20190321363A1
(en)
*
|
2016-06-20 |
2019-10-24 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of elagolix sodium and its polymorph
|
|
ES2898778T3
(es)
|
2016-07-21 |
2022-03-08 |
ObsEva SA |
Pautas posológicas de antagonistas de oxitocina para promover la implantación de embriones y prevenir aborto espontáneo
|
|
EP4094766A1
(en)
|
2016-09-30 |
2022-11-30 |
Myovant Sciences GmbH |
Methods of treating uterine fibroids and endometriosis
|
|
EP3518952A1
(en)
|
2016-09-30 |
2019-08-07 |
Myovant Sciences GmbH |
Methods of treating female infertility
|
|
BR112019006228A2
(pt)
|
2016-09-30 |
2019-06-18 |
Myovant Sciences Gmbh |
tratamento de câncer de próstata
|
|
EP3554526B1
(en)
|
2016-12-14 |
2024-05-08 |
Purdue Research Foundation |
Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
|
|
WO2018189212A1
(en)
|
2017-04-12 |
2018-10-18 |
Sandoz Ag |
Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist
|
|
EP3388421B1
(en)
|
2017-04-13 |
2019-12-04 |
Sandoz AG |
Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist
|
|
ES2770132T3
(es)
|
2017-04-13 |
2020-06-30 |
Sandoz Ag |
Dispersión sólida amorfa de un antagonista del receptor de la hormona liberadora de gonadotropina disponible por vía oral
|
|
WO2018198086A1
(en)
*
|
2017-04-28 |
2018-11-01 |
Lupin Limited |
Process for the preparation of elagolix and pharmaceutically acceptable salts thereof
|
|
SG11201911598WA
(en)
|
2017-06-05 |
2020-01-30 |
ObsEva SA |
Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
|
|
WO2018224063A2
(en)
*
|
2017-06-08 |
2018-12-13 |
Zentiva, K.S. |
Solid forms of elagolix
|
|
US20190054027A1
(en)
|
2017-08-18 |
2019-02-21 |
Abbvie Inc. |
Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
|
|
WO2019036712A1
(en)
|
2017-08-18 |
2019-02-21 |
Abbvie Inc. |
PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS
|
|
AU2018317472A1
(en)
*
|
2017-08-18 |
2020-03-05 |
Abbvie Inc. |
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
|
|
CN107935863A
(zh)
*
|
2017-11-30 |
2018-04-20 |
厦门海乐景生化有限公司 |
Elagolix的关键原料化合物C的合成方法
|
|
CN110938037A
(zh)
*
|
2018-09-21 |
2020-03-31 |
苏州鹏旭医药科技有限公司 |
一种依拉戈利钠盐药物中间体的制备方法
|
|
JP7200261B2
(ja)
*
|
2017-12-05 |
2023-01-06 |
スージョウ ポンシュー ファーマテック カンパニー リミテッド |
エラゴリクスを作製するプロセス
|
|
WO2019115019A1
(en)
|
2017-12-11 |
2019-06-20 |
Synthon B.V. |
Process for preparing elagolix
|
|
CN109970663B
(zh)
|
2017-12-27 |
2023-04-11 |
上海科胜药物研发有限公司 |
一种制备噁拉戈利中间体的方法
|
|
CN108129400B
(zh)
*
|
2017-12-29 |
2021-10-15 |
安帝康（无锡）生物科技有限公司 |
氘代噁拉戈利衍生物及其用途
|
|
CN112261942A
(zh)
|
2018-04-19 |
2021-01-22 |
艾伯维公司 |
治疗重度月经出血的方法
|
|
CN110669013A
(zh)
*
|
2018-07-03 |
2020-01-10 |
江苏海悦康医药科技有限公司 |
一种噁拉戈利中间体的制备方法
|
|
CA3104902A1
(en)
|
2018-07-23 |
2020-01-30 |
Abbvie Inc. |
Elagolix sodium compositions and processes
|
|
CA3107597A1
(en)
*
|
2018-08-01 |
2020-02-06 |
Abbvie Inc. |
Dosing regimens for elagolix
|
|
EP3572406A1
(en)
|
2018-10-17 |
2019-11-27 |
Sandoz Ag |
Acid addition salt of elagolix and related compounds
|
|
CA3117092A1
(en)
|
2018-10-29 |
2020-05-07 |
ObsEva S.A. |
Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
|
|
EP3876943A2
(en)
|
2018-11-07 |
2021-09-15 |
ObsEva S.A. |
Compositions and methods for the treatment of estrogen-dependent disorders
|
|
CN109293634A
(zh)
*
|
2018-12-04 |
2019-02-01 |
中国药科大学 |
恶拉戈利杂质的制备方法
|
|
CN109651171A
(zh)
*
|
2019-01-13 |
2019-04-19 |
苏州鹏旭医药科技有限公司 |
依拉戈利及其钠盐的中间体及其盐的制备方法和应用
|
|
WO2020150170A1
(en)
|
2019-01-15 |
2020-07-23 |
Lupin Inc. |
Deuterated elagolix-like compositions and methods
|
|
CN109761913A
(zh)
*
|
2019-02-16 |
2019-05-17 |
安徽华胜医药科技有限公司 |
一种有机金属钯催化合成elagolix中间体的方法
|
|
CN109651265A
(zh)
*
|
2019-02-16 |
2019-04-19 |
安徽诺全药业有限公司 |
一种Elagolix的制备方法
|
|
CN109810065B
(zh)
*
|
2019-02-16 |
2022-07-15 |
安徽华胜医药科技有限公司 |
一种恶拉戈利的合成方法
|
|
CN110041232A
(zh)
*
|
2019-04-10 |
2019-07-23 |
丽珠集团新北江制药股份有限公司 |
一种制备GnRHR药物关键中间体化合物的方法
|
|
CN109956906B
(zh)
*
|
2019-04-19 |
2021-01-29 |
奥锐特药业股份有限公司 |
一种噁拉戈利关键中间体的制备方法
|
|
WO2020240375A1
(en)
*
|
2019-05-24 |
2020-12-03 |
Dr. Reddy’S Laboratories Limited |
Improved process for the preparation of elagolix and its intermediates
|
|
CN110204498B
(zh)
*
|
2019-06-14 |
2020-11-27 |
奥锐特药业股份有限公司 |
一种高效合成噁拉戈利中间体的方法
|
|
CN110372608A
(zh)
*
|
2019-07-09 |
2019-10-25 |
丽珠集团新北江制药股份有限公司 |
一种促性腺激素释放激素拮抗剂的制备方法
|
|
ES2802815B2
(es)
|
2019-07-12 |
2022-03-14 |
Moehs Iberica Sl |
Sal clorhidrato de 3-[2(r)-amino-2-feniletil]-5-(2-fluoro-3-metoxifenil)-1-[2-fluoro-6-(trifluorometil)bencil]-6-metil-1h-pirimidin-2,4(1h,3h)-diona (i) en forma solida, procedimiento para su preparacion y uso de la misma en la sintesis de elagolix
|
|
CN110372609B
(zh)
*
|
2019-07-25 |
2021-04-09 |
奥锐特药业股份有限公司 |
一种噁拉戈利钠盐的纯化方法
|
|
CN112672998B
(zh)
*
|
2019-07-31 |
2022-06-21 |
深圳仁泰医药科技有限公司 |
恶拉戈利与乙胺嘧啶的共晶型a及其制备方法和用途
|
|
KR20220061120A
(ko)
|
2019-08-08 |
2022-05-12 |
옵스에파 에스에이 |
에스트로겐-의존성 장애 치료용 조성물 및 방법
|
|
KR20220045198A
(ko)
|
2019-08-08 |
2022-04-12 |
옵스에파 에스에이 |
에스트로겐-의존성 장애의 치료를 위한 gnrh 길항제
|
|
US11840519B2
(en)
|
2019-09-03 |
2023-12-12 |
Industriale Chimica S.R.L. |
Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process
|
|
IT201900015458A1
(it)
*
|
2019-09-03 |
2021-03-03 |
Ind Chimica Srl |
Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
|
|
AU2020340670A1
(en)
|
2019-09-03 |
2022-04-07 |
ObsEva S.A. |
Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
|
|
IT202000001390A1
(it)
*
|
2020-01-24 |
2021-07-24 |
Ind Chimica Srl |
Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo
|
|
TWI755055B
(zh)
*
|
2019-09-18 |
2022-02-11 |
台灣神隆股份有限公司 |
用於製備惡拉戈利鈉及其中間體的方法
|
|
WO2021064561A1
(en)
*
|
2019-10-03 |
2021-04-08 |
Neuland Laboratories Limited |
An improved process for the preparation of elagolix sodium
|
|
CN112694445B
(zh)
*
|
2019-10-22 |
2023-07-28 |
成都倍特药业股份有限公司 |
一种噁拉戈利钠中间体的纯化方法
|
|
ES2822398B2
(es)
*
|
2019-10-30 |
2022-03-02 |
Moehs Iberica Sl |
3-((R)-2-(Amino-2-feniletil)-1-(2-fluoro-6-trifluorometilbencil)-5-yodo-6-metil-1H-pirimidin-2,4-diona o una sal de la misma, procedimiento para su preparación y su uso en la síntesis de elagolix
|
|
US20230072265A1
(en)
*
|
2019-12-27 |
2023-03-09 |
Msn Laboratories Private Limited, R&D Center |
An improved process for the preparation of 4-({(1 r)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2 h)-yl]-1-phenylethyl}amino)butanoic acid or its pharmaceutically acceptable salts
|
|
CN113125575B
(zh)
*
|
2019-12-31 |
2023-04-18 |
济南尚博生物科技有限公司 |
一种1-(2-氟-6-(三氟甲基)苄基)-6-甲基嘧啶-二酮的定量分析方法
|
|
CN111116490A
(zh)
*
|
2020-01-15 |
2020-05-08 |
奥锐特药业股份有限公司 |
一种噁拉戈利中间体水杨酸盐的制备与纯化方法
|
|
CN115380122A
(zh)
|
2020-02-10 |
2022-11-22 |
奥布赛瓦股份公司 |
用于催产素受体拮抗剂疗法的生物标志物
|
|
JP2023516404A
(ja)
*
|
2020-03-05 |
2023-04-19 |
アッヴィ・インコーポレイテッド |
エラゴリクスの投与方法
|
|
WO2021180862A1
(en)
|
2020-03-12 |
2021-09-16 |
Synthon B.V. |
Pharmaceutical compositions comprising elagolix sodium
|
|
CN111333548B
(zh)
*
|
2020-04-10 |
2022-04-26 |
江苏海悦康医药科技有限公司 |
1-(2-氟-6-(三氟甲基)苄基)脲的制备方法
|
|
CN113527213B
(zh)
*
|
2020-04-20 |
2023-01-03 |
上海英诺富成生物科技有限公司 |
促性激素释放激素受体拮抗剂及其用途
|
|
CN113683572A
(zh)
*
|
2020-05-18 |
2021-11-23 |
陈晓雯 |
噁拉戈利的中间体及其制备方法和应用
|
|
CN112457258A
(zh)
*
|
2020-11-26 |
2021-03-09 |
诚达药业股份有限公司 |
一种噁拉戈利钠及其中间体的制备方法
|
|
EP4284374A1
(en)
|
2021-01-29 |
2023-12-06 |
Abbvie Inc. |
Methods of administrating elagolix
|
|
KR102656087B1
(ko)
|
2024-01-12 |
2024-04-09 |
주식회사 씨엠지 |
Led 소자의 에폭시 수지 코팅층 형성 방법
|
